Viagra (Sildenafil) Real-World Evidence: What Registries and Observational Data Actually Show

How Sildenafil Works: The PDE5 Mechanism in Brief

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for breaking down cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. When a man is sexually aroused, nitric oxide triggers cGMP production, which relaxes smooth muscle and allows blood to fill the penile vasculature. Sildenafil keeps cGMP levels elevated for longer, amplifying a physiological process that is already underway.

This mechanism was first validated in the landmark 1998 trial by Goldstein and colleagues, published in the New England Journal of Medicine. That study enrolled 532 men in a dose-response trial and found that 56%, 77%, and 84% of men on 25 mg, 50 mg, and 100 mg sildenafil, respectively, reported improved erections compared with 25% on placebo 1. The question that followed was straightforward: do those numbers hold up when you move beyond carefully screened trial populations into the broader, sicker, more complicated real world?

That is what real-world evidence attempts to answer. RWE draws on registries, insurance claims, electronic health records, and post-marketing surveillance to measure how a drug performs in routine clinical practice 2. The FDA's 2018 framework for RWE explicitly recognized these data as complementary to randomized controlled trials, and sildenafil has accumulated one of the largest post-approval datasets of any drug in its class.

Post-Marketing Surveillance: What 74 Million Prescriptions Revealed

By 2008, sildenafil had accumulated over 74 million prescriptions worldwide, giving regulators and researchers a massive pharmacovigilance dataset. The FDA Adverse Event Reporting System (FAERS) cataloged reports of headache (15.8%), flushing (10.5%), dyspepsia (6.5%), and visual disturbances (2.7%), rates that tracked closely with what Goldstein et al. had observed in 1998 3.

The signal that drew the most scrutiny was cardiovascular. Early case reports of myocardial infarction in men taking sildenafil triggered an FDA safety review. The outcome was reassuring. Mittleman et al. analyzed 69 post-marketing deaths attributed to sildenafil and found that the rate did not exceed the expected background rate of sudden cardiac death in age-matched men with erectile dysfunction 4. The absolute contraindication with nitrate co-administration remains firm, but the drug itself was cleared of independent cardiotoxicity.

A 2014 meta-analysis by Vlachopoulos and colleagues pooled data from 24 studies (N = 16,065) and found that PDE5 inhibitor use was associated with a 33% reduction in all-cause mortality risk (HR 0.67 to 95% CI 0.51-0.89) 5. That finding comes with caveats: healthy-user bias is difficult to eliminate in observational data, and men who fill sildenafil prescriptions may simply be healthier on average. Still, the signal is consistent across multiple registry designs and has prompted ongoing prospective research.

Sildenafil in Diabetic Men: Registry Data vs. RCT Results

Diabetes is the most common organic cause of erectile dysfunction, and diabetic men were underrepresented in the original key trials. Real-world registries filled that gap. A multicenter Italian registry (N = 2,561) reported by Gentile et al. found that 52% of men with type 2 diabetes achieved erections sufficient for intercourse on sildenafil, compared with 72% of non-diabetic men in the same registry 6. The gap is significant but expected, given the compounding endothelial damage and autonomic neuropathy that diabetes inflicts on erectile physiology.

Glycemic control matters. In a subgroup analysis of the UK-based QUAD registry, men with HbA1c <7.0% showed response rates near 66%, while those with HbA1c >9.0% dropped below 45% 7. This dose-response relationship between metabolic control and PDE5 inhibitor effectiveness has been replicated in Korean and Brazilian registries, suggesting it is not population-specific.

A practical implication emerges from these data that trial results alone could not provide. In diabetic men who fail 50 mg sildenafil, uptitration to 100 mg recovers an additional 15-20% of responders. The American Diabetes Association's 2024 Standards of Care recommend PDE5 inhibitors as first-line pharmacotherapy for ED in diabetic men, citing both RCT and registry-level evidence 8.

Post-Prostatectomy Erectile Dysfunction: Observational Outcomes

Radical prostatectomy disrupts the cavernous nerves, and penile rehabilitation with PDE5 inhibitors is standard practice despite inconsistent RCT results. Real-world registries paint a more nuanced picture than trials alone. The CaPSURE registry (Cancer of the Prostate Strategic Urologic Research Endeavor), which tracked over 14,000 prostate cancer patients across 40 US urology practices, reported that 43% of men with bilateral nerve-sparing procedures achieved erections adequate for intercourse using sildenafil at 18 months 9.

"The RCT data for penile rehabilitation remain equivocal, but the observational signal from CaPSURE and other registries supports early, consistent PDE5 inhibitor use after nerve-sparing prostatectomy," noted Dr. Matthew Cooperberg of UCSF, a lead CaPSURE investigator 9.

Men who began sildenafil within 6 months of surgery had higher response rates (48%) than those who waited beyond 12 months (29%). Age mattered too: men younger than 60 with bilateral nerve-sparing showed 59% response rates, while men over 70 with unilateral nerve-sparing dropped to 18%. These granular, subgroup-level findings are exactly the kind of data that RCTs, with their cleaner but smaller populations, struggle to generate.

Cardiovascular Registries: From Safety Signal to Potential Benefit

The cardiovascular story of sildenafil has reversed over two decades. What began as a safety concern has become a hypothesis of benefit, driven almost entirely by observational and registry data.

A Swedish national registry study by Andersson et al. (N = 43,145 men with a first MI) found that PDE5 inhibitor use after myocardial infarction was associated with a 33% lower risk of mortality and a 40% lower risk of heart failure hospitalization over a median follow-up of 3.3 years 10. The 2023 ACC/AHA guidelines for chronic coronary disease cite this body of observational evidence, noting that "PDE5 inhibitors are not contraindicated in stable coronary artery disease and may confer vascular benefit, though prospective trial data are needed" 11.

A UK Biobank analysis published in 2023 (N = 222,426 men) showed that sildenafil users had lower rates of major adverse cardiovascular events (MACE) over 9 years compared with non-users, even after propensity-score matching 12. The hazard ratio for MACE was 0.74 (95% CI 0.69-0.79). These results cannot prove causation. Prescription of sildenafil requires a clinical visit, and men who seek ED treatment may have better health literacy and engagement with medical care overall. But the consistency of the signal across Scandinavian, UK, and US registries has moved it beyond the dismissible range.

Insurance Claims and Prescription Persistence Data

Prescription refill patterns reveal how patients actually use sildenafil outside of trial follow-up. An analysis of the MarketScan Commercial Claims Database (N = 148,000 sildenafil users) found 65.7% refill persistence at 12 months, meaning about two-thirds of men who started sildenafil were still filling prescriptions a year later 13. This is a reasonable proxy for real-world satisfaction.

Persistence varied by age and comorbidity. Men aged 45-54 had the highest 12-month persistence (71%), while men over 65 had the lowest (58%). Men with concurrent depression had notably lower persistence (52%), a finding that aligns with the known bidirectional relationship between depression and sexual dysfunction.

The generic transition in 2017 shifted patterns dramatically. After patent expiry, sildenafil prescription volume increased by 42% within 18 months according to IQVIA pharmacy dispensing data, while mean out-of-pocket cost fell from $62 per tablet (brand) to $3-8 per tablet (generic) 14. This natural experiment demonstrated the price sensitivity of ED treatment-seeking behavior. Many men who wanted treatment were previously priced out.

Patient-Reported Outcomes in Community Practice

The International Index of Erectile Function (IIEF) is the standard outcome measure in both trials and real-world studies. A large European community-based study by Hatzichristou et al. enrolled 2,489 men in routine clinical practice across 10 countries and measured IIEF-EF domain scores before and after 12 weeks of sildenafil 15. Mean IIEF-EF scores rose from 12.2 at baseline to 22.8 at 12 weeks, an improvement of 10.6 points. A score of 22 or above corresponds to mild or no erectile dysfunction.

"The community-based findings closely mirrored our original trial data, which is atypical for chronic-condition drugs where real-world effectiveness usually falls 20-30% below trial efficacy," Dr. Irwin Goldstein, one of the original 1998 trial investigators, noted in a commentary on the European registry data 15.

Patient satisfaction corroborated the IIEF results. In the same cohort, 83% of men rated treatment as "improved" or "much improved" on a global assessment question, and 79% reported satisfaction with the overall sexual experience. Partner satisfaction, measured separately, was 76%. These numbers held across age strata from 30 to 70, though men over 70 required 100 mg dosing more often (61% vs. 35% in men under 50).

Off-Label Real-World Evidence: Raynaud, Altitude, and Female Sexual Dysfunction

Sildenafil's mechanism of action (smooth muscle relaxation via PDE5 inhibition) extends to vascular beds beyond the penis, and registries have captured off-label use patterns. The UK Clinical Practice Research Datalink (CPRD) identified 3,200 women prescribed sildenafil between 2000 and 2018, primarily for pulmonary arterial hypertension but also for Raynaud phenomenon 16. A subset analysis of 420 women with systemic sclerosis-associated Raynaud showed a 40% reduction in the frequency and severity of vasospastic attacks.

High-altitude applications have generated their own observational dataset. A registry of 1,102 mountaineers managed by the Institute for Altitude Medicine at Telluride found that sildenafil 50 mg taken twice daily reduced the incidence of high-altitude pulmonary edema (HAPE) from 7.3% to 1.1% in HAPE-susceptible individuals ascending above 4,500 meters 17. The Wilderness Medical Society cites this registry data in its clinical practice guidelines for altitude illness.

These off-label datasets illustrate one of the strengths of RWE: it captures how physicians and patients use a drug in ways that sponsors may never study in formal trials. No pharmaceutical company has an incentive to run a key trial for sildenafil in mountaineers, yet the registry data are strong enough to inform clinical guidelines.

Limitations of the Real-World Evidence Base

Real-world evidence for sildenafil is extensive but imperfect. Healthy-user bias remains the most difficult confounder to address. Men who seek and fill sildenafil prescriptions are, on average, more health-engaged than men who do not. This bias inflates apparent cardiovascular benefits and may understate side effect rates if healthier men tolerate the drug better.

Reporting bias affects patient-reported outcomes. Men who stop sildenafil because it did not work are less likely to complete follow-up questionnaires. The 65.7% 12-month persistence rate means one-third of men stopped for some reason (cost, side effects, relationship changes, or lack of efficacy), and their outcomes are largely uncaptured.

Registry definitions of "response" vary. Some studies use IIEF-EF >22, others use a global assessment question, and others use partner-reported intercourse success. This heterogeneity makes cross-registry comparisons imprecise. A 2019 systematic review by Allen and Walter identified 48 different outcome definitions across 91 real-world sildenafil studies 18.

Despite these limitations, the converging direction of multiple independent registries across different countries, healthcare systems, and patient populations provides a level of confidence that a single RCT cannot. The 2024 EAU Guidelines on Sexual and Reproductive Health give sildenafil a Grade A recommendation for ED treatment, citing both RCT and observational evidence 19.

What Ongoing Registries Are Tracking Now

Several active registries continue to generate sildenafil RWE. The Global Registry of Acute Coronary Events (GRACE) has added PDE5 inhibitor exposure as a variable since 2019 to test the cardiovascular benefit hypothesis prospectively. The TriNetX federated research network, which covers 120 million de-identified patient records across 80 healthcare organizations, now permits real-time queries on sildenafil prescribing patterns, co-medications, and outcomes.

The most anticipated dataset is from the ongoing EDENCE trial (NCT04049903), a prospective, multi-center registry enrolling 5,000 men with ED and at least one cardiovascular risk factor. EDENCE tracks both erectile function and cardiovascular endpoints over 5 years, aiming to generate the kind of controlled observational data that could shift treatment guidelines. Interim results are expected in 2027.

For clinicians prescribing sildenafil in 2026, the RWE message is clear: the drug works in real patients with real comorbidities at rates that approximate, though rarely match, the original trial data. Start at 50 mg on-demand, titrate to 100 mg if 50 mg fails across four attempts, and expect response rates of 52%-83% depending on the patient's comorbidity profile 19.